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Aims To assess the risk of acute pancreatitis associated with use of acid-suppressing
drugs.
Methods We conducted a retrospective cohort study with a nested case-control design
within the General Practice Research Database (GPRD) in the United Kingdom. The
cohort included 180 178 persons aged 20–74 years, who had received at least one
prescription of cimetidine, famotidine, nizatidine, ranitidine, lansoprazole, or
omeprazole from January 1992 to September 1997 and who did not have major
risk factors for pancreatic diseases. Patients with a computerized medical history
compatible with idiopathic acute pancreatitis were validated through review of
medical records. For the nested case-control analysis 1000 controls were randomly
selected from the study population.
Results We identified 88 potential cases of idiopathic acute pancreatitis. Medical
records were available for 86. After review of these records 36 cases of acute
pancreatitis were confirmed. Seven cases occurred during nonuse, corresponding to a
background incidence rate (IR) of 4.4/100 000 person-years (PY). Six cases occurred
during current use of ranitidine (IR 10.5/100 000 PY), five patients were current users
of cimetidine (IR 13.9/100 000 PY), and three were current users of omeprazole (IR
7.8/100 000 PY). There were no cases among current users of famotidine,
lansoprazole, or nizatidine. Relative risk (RR) compared with nonuse and corrected
for age, gender, calendar year and use of medication known to be associated with acute
pancreatitis was 1.3 (95% CI: 0.4,4.1) for ranitidine, 2.1 (95% CI: 0.6,7.2) for
cimetidine, and 1.1 (95% CI: 0.3,4.6) for omeprazole.
Conclusions The results of this study do not support an association between acute
pancreatitis and the use of acid-suppressing drugs, although a substantial increase in risk
cannot be excluded with confidence.
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Introduction
Several drugs have been implicated as possible causes of
acute pancreatitis [1–3]. Most information on drug-
induced acute pancreatitis is derived from anecdotal
case-reports, and very little is known about the incidence
and mechanisms of drug-induced acute pancreatitis.
Cimetidine, famotidine, nizatidine, ranitidine, lanso-
prazole, and omeprazole are extensively used in the
treatment of peptic ulcer disease, and reflux oesophagitis.
Adverse drug reactions affecting the central nervous
system, kidneys, haematological system, gastrointestinal
tract and the cardiovascular system have been attributed to
these acid-suppressing drugs [4]. Cimetidine and ranitidine
have been associated with acute pancreatitis in several
case-reports [5–9]. Although a relationship was found
between cimetidine and acute pancreatitis in rats [10],
others have questioned this [11]. A record-linkage case-
control study showed a crude significant association
between cimetidine, ranitidine and acute pancreatitis,Received 9 August 1999, accepted 16 February 2000.
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but this association disappeared after adjustment for
potential confounders [12].
In view of the controversies regarding the association
between acid-suppressing drugs and acute pancreatitis, we
conducted a retrospective cohort study in the General
Practice Research Database (GPRD) in the United
Kingdom (UK) to assess the risk of acute pancreatitis
associated with the use of cimetidine, famotidine,
nizatidine, ranitidine, lansoprazole, and omeprazole. A
nested case-control analysis was conducted to examine in
more detail the relationship between dose and duration of
treatment, and the risk of acute pancreatitis.
Methods
Setting
Over 4 million residents in the UK are registered with
general practitioners (GPs) who participate in the GPRD
database. Medical data on these 4 million patients are
continuously recorded and sent anonymously to the Office
of National Statistics (ONS) for use in research projects.
The computerized information contains demographic
data, general practitioner consultations, referrals to con-
sultants and hospitals, and all prescriptions issued. Indica-
tions for new courses of treatment are routinely stored in
the database. In addition, the GP may record laboratory
test results and other medical data in a free text comment
field. A modification of the Oxford Medical Information
System (OXMIS) classification is used to code specific
diagnoses. Previous validation studies have found that over
90% of all referrals are recorded with a code that reflects
the specialist’s diagnosis [13, 14]. Drugs are coded
according to a drug dictionary based on data from the
Prescription Pricing Authority.
Source population
The source population consisted of all patients aged
20–74 years registered with 337 general practitioner
practices with a permanent registration status during the
study period January 1st 1992 and September 30th 1997.
Study cohort
The study cohort comprised all patients who received at
least one prescription for cimetidine, famotidine, nizati-
dine, ranitidine, lansoprazole, or omeprazole during the
study period. We excluded all subjects with a history of
acute pancreatitis or assessment of amylase before the date
of the first prescription of a study drug. Patients with a
diagnosis of cancer, alcoholism, biliary-or pancreatic
diseases, and biliary or pancreatic surgical procedures
within 5 years before study entry were also removed from
the cohort. The remaining patients were followed from
the date of the first prescription of one of the study drugs
to the earliest of the following events: development of
acute pancreatitis, assessment of amylase, one of the above
mentioned clinical exclusion criteria, death, or end of the
study period.
Case ascertainment
With a computerized search, we identified all study
members who had a code for acute pancreatitis or a code
for assessment of amylase. Subsequently, the complete
computerized patient profiles blinded to drug exposure
were manually reviewed to exclude all patients who were
not referred to a specialist or hospital, all patients with a
diagnosis of cancer, alcoholism, cholelithiasis, postopera-
tive pancreatitis, other pancreatic disorders, and all patients
in whom the diagnosis of acute pancreatitis was clearly
excluded. Potential cases were those for whom the
information in the patient profiles was compatible with
idiopathic acute pancreatitis.
Case validation
We requested the medical records of all potential cases
(n=88) from the GPs. Received records were, indepen-
dently and blinded to exposure, validated by all four
authors. Based on this information, we excluded all
individuals who had any evidence of alcohol abuse,
cholelithiasis, chronic pancreatitis, malignant neoplasms,
any other well-defined condition associated with the
development of acute pancreatitis, or if symptoms of acute
pancreatitis started before start of follow-up. Consensus
was reached on all cases. The diagnosis was accepted when
acute pancreatitis was explicitly mentioned in the
discharge letter or when there was a clinical picture
compatible with acute pancreatitis together with one of
the following criteria: an increase in serum amylase or
lipase of >2 times the upper limit of normal, confirmatory
evidence of acute pancreatitis at imaging procedures or at
laparotomy or autopsy.
Cohort analysis
Person-time contributed by the study participants was
divided into three mutually exclusive categories: current
use, past use and nonuse. Current use was defined as the
person time experienced during the length of an acid-
suppressing drug prescription and 6 days thereafter. Past
use included the period up to 365 days after the end of
current use. Consequently, the time window of nonuse
started at the end of past use. Incidence rates were
calculated by dividing the total number of cases of acute
pancreatitis by the corresponding total amount of person-
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time experienced. Ninety-five percent confidence inter-
vals (95% CIs) were calculated based on a Poisson
distribution.
Adjusted estimates of relative risks and its 95% CIs
associated with current and past use as compared with
nonuse were computed using a Poisson regression model
with age, sex, and calendar year included in the model.
Nested case-control analysis
In order to explore dose and duration effects we
performed a nested case-control analysis within the
study cohort. All confirmed cases were used in the
nested case-control analysis. The index date for the cases
was the date of start of symptoms compatible with acute
pancreatitis (same index date as used in the cohort
analysis). In order to ascertain controls, a random date
during the study period was generated for all study
participants. A subject was an eligible control when the
random date was included in his or her follow-up time. All
exclusion criteria applied to the selection of the cases were
also applied to the controls. From the list of eligible
controls, we randomly selected 1000 controls and their
random date was defined as the index date.
A participant was defined as a current user of one of the
study drugs if the index date fell within the prescription
period or when the end date of the last prescription fell
within 6 days preceding the index date. A person was
defined as a past user when the end date of the last
consecutive prescription period fell within 7 to 371 days
before the index date. A person was defined as a nonuser
when none of the study drugs were used in the 371 days
preceding the index date. Estimates of the odds ratios and
their 95% CIs were calculated by logistic regression
analyses comparing current and past use with nonuse of
the individual acid-suppressing drugs. Age, sex, calendar
year, and presence of other drugs associated with
acute pancreatitis [3] (ACE-inhibitors, aminosalicylates,
NSAIDs, oestrogens, frusemide, thiazide diuretics, val-
proic acid, and azathioprine) were included in the model
to control for potential confounding.
Results
The study cohort consisted of 180 178 subjects who
received at least one prescription of cimetidine, famoti-
dine, nizatidine, ranitidine, lansoprazole, or omeprazole.
Overall 1 545 921 prescriptions of these acid-suppressing
drugs were written during the study period. The age and
gender distribution of users of individual acid-suppressing
drugs is presented in Table 1. There were 88 patients who
had a computerized history compatible with an idiopathic
Table 1 Age and gender distribution: all numbers refer to number of acid-suppressing drug prescriptions.
Total Male Female 20–59years 60–74years
Overall 1 545 921 52% 48% 51% 49%
Cimetidine 382 767 52% 48% 51% 49%
Famotidine 16 797 52% 48% 50% 50%
Lansoprazole 54 554 51% 49% 57% 43%
Nizatidine 49 079 51% 49% 51% 49%
Omeprazole 439 104 50% 50% 51% 49%
Ranitidine 603 620 53% 47% 49% 51%
Table 2 Incidence rates of and relative risks of acute pancreatitis for individual acid-suppressing drugs.
Person-years Cases IR/105 Crude RR (95% CI) RR (95% CI)*
Non-users{ 160430 7 4.4
Current-use{ 141738 14 9.9 2.3 (0.9,5.6) 1.6 (0.6,4.2)
cimetidine 35966 5 13.9 3.2 (1.0,10.0) 2.3 (0.7,7.7)
famotidine 1551 0 –
lansoprazole 4567 0 –
nizatidine 4262 0 –
omeprazole 38430 3 7.8 1.8 (0.5,6.9) 1.3 (0.3,5.3)
ranitidine 56961 6 10.5 2.4 (0.8,7.2) 1.7 (0.6,5.4)
Past use· 196356 15 7.6 1.8 (0.7,4.3) 1.6 (0.6,4.0)
* Age, gender and calendar year were included in the Poisson regression model. { No use of an acid-suppressing drug in the 371 days preceding
the index date. { Use of an acid-suppressing drug on the index date or the 6 days preceding the index date. · Use of an acid-suppressing drug in
days 7–371 before the index date.
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episode of acute pancreatitis and for whom medical
records were requested from the GPs. No information was
received for two patients. Of the remaining 86 patients, 36
(42%) were classified as cases. The remainder were
excluded because of alcohol abuse (n=11), cholelithiasis
(n=10), cancer, other pancreatic disorders and post-
operative pancreatitis in 11 patients. The diagnosis of acute
pancreatitis was not confirmed in 11 patients. In the
remaining seven patients onset of symptoms was before the
start of follow-up.
The overall incidence rate of idiopathic acute pancrea-
titis during current use of acid-suppressing drugs was 9.9
(95% CI: 4.7,15.1) per 100 000 person years (PY), 7.6
(95% CI: 3.8,11.5) per 100 000 PY for past users, and 4.4
(95% CI: 1.1,7.6) per 100 000 PY for nonusers. After
adjustment for age, gender and calendar year the RR was
1.6 (95% CI: 0.6,4.2) for current use and 1.6 (95% CI:
0.6,4.0) for past use of an acid-suppressing drug. Incidence
rates and RRs for individual acid-suppressing drugs are
given in Table 2.
Table 3 shows the results of the nested case-control
analysis. Out of the 36 cases, 20 (56%) were male and the
mean age was 61 years. Use of acid-suppressing drugs,
gender and calendar year were not significantly associated
with acute pancreatitis. The RR among current users of
medications suspected to be associated with acute
pancreatitis was 2.0 (95% CI: 1.0,4.2). Age was the only
factor that was significantly associated with the occurrence
of acute pancreatitis. Although not significant, the risk of
acute pancreatitis was higher in the first month of acid-
suppressing therapy: 2.3 (95% CI: 0.5,9.5) vs 1.1 (95% CI:
0.4,3.3) for long-term users. Exclusion of all current users
of medications thought to be associated with acute
pancreatitis did not change the risk estimates considerably
(data not shown). A dose–response relationship was not
observed in users of cimetidine or ranitidine (Table 4).
Discussion
In this large cohort study, we observed no significant
increased risk of acute pancreatitis in users of acid-
suppressing drugs. Cimetidine was the only individual
acid-suppressing drug with a significantly increased risk of
acute pancreatitis, but this association was no longer
present after adjustment for potential confounders. There
was a tendency towards an increased risk in the first month
of treatment. The daily dosage of acid-suppressing drugs
had no effect on the risk of acute pancreatitis.
The validity of epidemiological studies may suffer from
selection bias, information bias or confounding. The
presence of selection bias in this study is unlikely as
identification of the study population was based on
prerecorded prescriptions of acid-suppressing drugs, and
therefore unrelated to the outcome of interest. Since drug
Table 3 Relative risk of acute pancreatitis associated with use of acid-suppressing drugs and other factors.
Cases (n=36) Controls (n=1000) OR (95% CI)
Acid-suppressing drug
Non-use{ 7 306
Current use{ 14 263 1.4 (0.5,3.6)
cimetidine 5 65 2.1 (0.6,7.2)*
omeprazole 3 69 1.1 (0.3,4.6)*
ranitidine 6 129 1.3 (0.4,4.1)*
Past users· 15 431 1.3 (0.5,3.3)*
Age
20–59 years 12 639
60–74 years 24 361 3.1 (1.5,6.4)
Gender
Male 20 486
Female 16 514 0.6 (0.3,1.2)
Year category||
1992–94 16 400
1995–97 20 600 0.9 (0.5,1.8)
Pancreatoxic medication
Non-use 21 760
Current use 15 240 2.0 (1.0,4.2)
*Adjusted for age, gender, calendar year, and current use of other pancreatoxic medication.
{ No use of an acid-suppressing drug in the 371 days preceding the index date.
{ Use of an acid-suppressing drug on the index date or within the 6 days preceding the index date.
· Use of an acid-suppressing drug in days 7–371 before the index date.
|| End of study in September 1997.
I. A. Eland et al.
476 f 2000 Blackwell Science Ltd Br J Clin Pharmacol, 49, 473–478
exposure was recorded before the onset of disease, recall
bias is not present. Case histories concerning the
relationship between H2-receptor blockers and acute
pancreatitis have been published since the late seventies,
some of them proven by recurrence of symptoms after
restart of treatment [6, 9]. Physicians may therefore
diagnose acute pancreatitis more easily in patients using
these H2-receptor blockers. This diagnostic bias might
therefore explain the nonsignificant increase in RR of
cimetidine and ranitidine seen in this study. Patients with
gastric acid related diseases will pay more visits to
gastroenterological consultants and may therefore have
acute pancreatitis more easily detected. However, as none
of the acute pancreatitis diagnoses was made during
routine check-ups of antiulcer treatment we expect
diagnostic bias to play a minor role, if any, in explaining
the results. Misclassification of outcome was limited due to
review of the medical records of potential cases.
Misclassification of exposure, for instance by noncom-
pliance or dispensing of acid-suppressing drugs in hospital
was probably nondifferential and would therefore have
biased the risk estimates towards null. By restricting the
study to people without major risk factors for acute
pancreatitis we tried to control for confounding by these
factors.
A recent study on the association between H2-receptor
antagonists and acute pancreatitis reported a nonsignificant
RR of 3.7 for cimetidine and a nonsignificant RR of 3.1
for ranitidine [12]. In patients without risk factors for acute
pancreatitis these figures were 2.0 and 2.5, respectively.
The authors concluded that the higher RRs might be due
to residual confounding. Prescribing of acid-suppressing
drugs for prodromal symptoms of acute pancreatitis,
sometimes referred to as protopathic bias could be an
alternative explanation for the small increased risk seen in
the former study and in our study. We tried to reduce the
role of protopathic bias by taking the day of onset of
symptoms as index date for patients with acute pancreatitis.
The risk in the first 30 days of therapy was somewhat
higher than the risk thereafter, albeit nonsignificantly. This
could indicate either an acute effect or imperfect control of
protopathic bias. However, protopathic bias cannot
explain the different risk estimates for the different acid-
suppressing drugs as this form of selection bias would affect
all the acid-suppressing drugs alike.
In conclusion, the results of this study do not support an
association between acute pancreatitis and the use of acid-
suppressing drugs, although a substantial increase in risk
cannot be excluded with confidence.
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